

# Renuka Iyer

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8925548/renuka-iyer-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

35  
papers

870  
citations

15  
h-index

29  
g-index

38  
ext. papers

1,186  
ext. citations

4.8  
avg. IF

4.19  
L-index

#	Paper	IF	Citations
35	Mutant - and -Driven Hematopoiesis Populates the Hematopoietic Compartment in Response to Peptide Receptor Radionuclide Therapy.. <i>JCO Precision Oncology</i> , <b>2022</b> , 6, e2100309	3.6	0
34	Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair. <i>Communications Biology</i> , <b>2021</b> , 4, 862	6.7	0
33	Immunotherapy in hepatocellular cancer. <i>Advances in Cancer Research</i> , <b>2021</b> , 149, 295-320	5.9	
32	A phase I study of the anaplastic lymphoma kinase inhibitor ceritinib in combination with gemcitabine-based chemotherapy in patients with advanced solid tumors. <i>International Journal of Cancer</i> , <b>2021</b> , 149, 2063-2074	7.5	1
31	Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma. <i>Oncologist</i> , <b>2020</b> , 25, e1825-e1836	5.7	4
30	Exploring the role of survivin in neuroendocrine neoplasms. <i>Oncotarget</i> , <b>2020</b> , 11, 2246-2258	3.3	8
29	Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4317-4345	2.2	112
28	Sequencing Systemic Therapy Pathways for Advanced Hepatocellular Carcinoma: A Cost Effectiveness Analysis. <i>Liver Cancer</i> , <b>2020</b> , 9, 549-562	9.1	4
27	Interleukin-6 as a biomarker in patients with hepatobiliary cancers. <i>Journal of Gastrointestinal Oncology</i> , <b>2019</b> , 10, 537-545	2.8	2
26	Multidisciplinary Management of Patients with Unresectable Hepatocellular Carcinoma: A Critical Appraisal of Current Evidence. <i>Cancers</i> , <b>2019</b> , 11,	6.6	10
25	Augmentation of IFN- $\gamma$ CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy. <i>JCI Insight</i> , <b>2019</b> , 4,	9.9	34
24	Poly(ADP-Ribose) Polymerase Inhibitors in Pancreatic Cancer: A New Treatment Paradigms and Future Implications. <i>Cancers</i> , <b>2019</b> , 11,	6.6	23
23	Role of Adjuvant Chemotherapy in Pulmonary Carcinoids: An NCDB Analysis. <i>Anticancer Research</i> , <b>2019</b> , 39, 6835-6842	2.3	8
22	Woodchuck VEGF (wVEGF) characteristics: Model for angiogenesis and human hepatocellular carcinoma directed therapies. <i>Archives of Biochemistry and Biophysics</i> , <b>2019</b> , 661, 97-106	4.1	3
21	Immunomodulation in hepatocellular cancer. <i>Journal of Gastrointestinal Oncology</i> , <b>2018</b> , 9, 208-219	2.8	16
20	Management of Typical and Atypical Pulmonary Carcinoids Based on Different Established Guidelines. <i>Cancers</i> , <b>2018</b> , 10,	6.6	28
19	A phase 1, open-label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignancies. <i>Cancer</i> , <b>2018</b> , 124, 3890-3899	6.4	3

18	Clinicopathological characteristics and outcomes of rare histologic subtypes of gallbladder cancer over two decades: A population-based study. <i>PLoS ONE</i> , <b>2018</b> , 13, e0198809	3.7	24
17	NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2017</b> , 15, 563-573	7.3	207
16	Gemcitabine and capecitabine for advanced biliary cancer. <i>Journal of Gastrointestinal Oncology</i> , <b>2017</b> , 8, 728-736	2.8	4
15	A phase II trial of erlotinib monotherapy in advanced pancreatic cancer as a first- or second-line agent. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2017</b> , 80, 497-505	3.5	9
14	PD-1 and Foxp3 T cell reduction correlates with survival of HCC patients after sorafenib therapy. <i>JCI Insight</i> , <b>2016</b> , 1,	9.9	45
13	Endothelial progenitor cell number and ERK phosphorylation serve as predictive and prognostic biomarkers in advanced hepatocellular carcinoma patients treated with sorafenib. <i>Oncolmmunology</i> , <b>2016</b> , 5, e1226718	7.2	9
12	Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors. <i>Current Oncology Reports</i> , <b>2016</b> , 18, 7	6.3	28
11	Ki67 score as a potential predictor in the selection of liver-directed therapies for metastatic neuroendocrine tumors: a single institutional experience. <i>Journal of Gastrointestinal Oncology</i> , <b>2016</b> , 7, 441-8	2.8	14
10	Molecular Targets in Biliary Carcinogenesis and Implications for Therapy. <i>Oncologist</i> , <b>2015</b> , 20, 742-51	5.7	13
9	Targeted therapy in gastrointestinal malignancies. <i>Journal of Carcinogenesis</i> , <b>2014</b> , 13, 4	1.9	5
8	Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review. <i>Journal of Gastrointestinal Oncology</i> , <b>2014</b> , 5, E30-3	2.8	38
7	Breast cancer resistance protein (BCRP) and excision repair cross complement-1 (ERCC1) expression in esophageal cancers and response to cisplatin and irinotecan based chemotherapy. <i>Journal of Gastrointestinal Oncology</i> , <b>2014</b> , 5, 253-8	2.8	6
6	Quality of life and hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , <b>2014</b> , 5, 296-317	2.8	34
5	Quality-of-life (QoL) as a predictive biomarker in patients with advanced pancreatic cancer (APC) receiving chemotherapy: results from a prospective multicenter phase 2 trial. <i>Journal of Gastrointestinal Oncology</i> , <b>2014</b> , 5, 433-9	2.8	7
4	Erlotinib and radiation therapy for elderly patients with esophageal cancer - clinical and correlative results from a prospective multicenter phase 2 trial. <i>Oncology</i> , <b>2013</b> , 85, 53-8	3.6	19
3	A review of erlotinib--an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor. <i>Expert Opinion on Pharmacotherapy</i> , <b>2010</b> , 11, 311-20	4	28
2	Sorafenib: a clinical and pharmacologic review. <i>Expert Opinion on Pharmacotherapy</i> , <b>2010</b> , 11, 1943-55	4	104
1	Combined hepatocholangiocarcinoma: case-series and review of literature. <i>International Journal of Gastrointestinal Cancer</i> , <b>2006</b> , 37, 27-34		20

